Efficacy and safety of topical OPA‐15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double‐blind, placebo‐controlled study

The efficacy and safety of topical OPA‐15406, a new phosphodiesterase 4 inhibitor, were examined in Japanese patients aged 15–70 years with atopic dermatitis in a phase 2, randomized, double‐blind, vehicle‐controlled study. Two hundred patients were randomized to three treatment groups at a 1:1:1 ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeki, Hidehisa, Kawashima, Makoto, Sugaya, Satoko, Oshiden, Kazuhide, Tsubouchi, Hidetsugu, Onozuka, Takashi, Takahashi, Yoshimasa, Takata, Hideyasu, Yoshihara, Nobuko, Toyofuku, Kazutomo, Kitahara, Hiroto, Izumi, Tatsuya, Nogita, Toshitatsu, Yamamoto, Aisaku, Nakasu, Ichiro, Kume, Akihiro, Sasase, Akihiro, Watanabe, Masako, Houki, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771806/
https://www.ncbi.nlm.nih.gov/pubmed/34263481
http://dx.doi.org/10.1111/1346-8138.14979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771806/
https://www.ncbi.nlm.nih.gov/pubmed/34263481
http://dx.doi.org/10.1111/1346-8138.14979

Ejemplares similares